An interventional study of Regional citrate anticoagulation and Unfractionated heparin in End-Stage Kidney Disease, Hemodiafiltration and Chronic Hemodialysis, sponsored by University Medical Centre Ljubljana. Not yet recruiting at 1 site in Slovenia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-01.
Sponsored by University Medical Centre Ljubljana · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Kidney Failure, Chronic with a site in Slovenia — 2 open to participants now, 2 under way, none of them phase 3. Kidney Failure, Chronic · Slovenia.
Among the 13 studies in Kidney Failure, Chronic with a site in Slovenia, this one is the 10th largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2026, is one of 8 with no phase, and was the 13th registered.
2,115 studies on the registry are indexed under Kidney Failure, Chronic; 277 are open to participants now.
Browse Kidney Failure, Chronic studies →2 of the 13 studies in Kidney Failure, Chronic with a site in Slovenia are open now. Recruiting first, the newest first:
Rigshospitalet, Denmark · Sites in Slovenia, Argentina, Austria and 33 more countries
Ages 16+
A study can be open while its sites in Slovenia have not opened yet or have stopped. Only those recruiting at a site in Slovenia →
Of the 170 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 1994; this study’s year is marked. 1 started in 2026.
This study's planned enrollment of 20 is below the median of 57 across 1,573 interventional studies indexed under Kidney Failure, Chronic.
Median enrollment 50 across the 11 interventional studies, 12,543 across the 2 observational. Of the 6 that completed or were terminated, 1 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 13 have an industry lead sponsor. The 8 most frequent:
University Medical Centre Ljubljana is the lead sponsor of 298 studies on the registry; 73 are open to participants now.
University Medical Centre Ljubljana has 6 studies filed under Kidney Failure, Chronic — fewer than ten, so there is no comparison to draw.
1 of the studies in Kidney Failure, Chronic with a site in Slovenia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07618858University Medical Centre LjubljanaComparison of Citrate and Heparin Anticoagulation During Postdilution Hemodiafiltration | 2026-12-15 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies in Kidney Failure, Chronic with a site in Slovenia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This randomized crossover clinical trial will compare regional citrate anticoagulation (RCA) and standard heparin anticoagulation (HA) during postdilution hemodiafiltration (HDF) in chronic dialysis patients with end-stage kidney disease.
The primary aim of the study is to evaluate biocompatibility during HDF by measuring markers of complement activation (C3a), platelet activation (PF4), and coagulation activation (thrombin-antithrombin complex, TAT).
Secondary aims include comparison of solute removal efficiency, including beta-2 microglobulin, phosphate, and urea removal, as well as assessment of citrate, calcium, and magnesium kinetics during citrate anticoagulation.
Twenty adult chronic dialysis patients will undergo two study HDF procedures in randomized order: one procedure using heparin anticoagulation and one procedure using regional citrate anticoagulation with a one-week interval between procedures.
The study aims to improve understanding of the effects of anticoagulation methods on hemodiafiltration biocompatibility and dialysis efficiency and may contribute to optimization of citrate anticoagulation protocols in chronic hemodiafiltration patients.
Hemodiafiltration (HDF) is an advanced renal replacement therapy combining diffusion and convection, allowing improved removal of middle and larger molecular weight solutes compared with standard hemodialysis. During extracorporeal circulation, blood contact with artificial membranes and tubing activates complement, platelets, leukocytes, and coagulation pathways, requiring anticoagulation during the procedure.
Unfractionated heparin is routinely used for anticoagulation during HDF. Regional citrate anticoagulation (RCA) is mainly used in patients at increased bleeding risk. Previous studies in hemodialysis have suggested that citrate anticoagulation may improve biocompatibility because many blood-material interactions are calcium- and magnesium-dependent. However, biocompatibility during HDF using citrate versus heparin anticoagulation has not been systematically investigated.
This prospective randomized crossover clinical trial will include 20 adult patients with end-stage kidney disease receiving maintenance postdilution hemodiafiltration three times weekly. Patients will be randomized to one of two anticoagulation sequences: heparin-citrate or citrate-heparin. Each participant will undergo two study HDF procedures separated by a one-week interval.
During heparin anticoagulation, unfractionated heparin will be administered according to body weight using standard clinical protocols. During citrate anticoagulation, 8% trisodium citrate infusion and calcium-free dialysate will be used, with continuous calcium chloride substitution adjusted according to ionized calcium levels.
Biocompatibility markers including complement activation marker C3a, platelet factor 4 (PF4), thrombin-antithrombin complex (TAT), blood cell counts, and coagulation parameters will be assessed before HDF, after 15 minutes, and at the end of the procedure.
Dialysis efficiency will be evaluated by measurement of reduction ratios and total removal of beta-2 microglobulin, phosphate, and urea using partial dialysate collection methodology.
Additional secondary outcomes include assessment of citrate, calcium, and magnesium kinetics during RCA-HDF, visual clotting score evaluation of the extracorporeal circuit, and optimization of citrate anticoagulation protocols during postdilution HDF.
The study may contribute to improved understanding of anticoagulation-related biocompatibility during HDF and support wider evidence-based use of regional citrate anticoagulation in chronic dialysis patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants will undergo postdilution hemodiafiltration using regional citrate anticoagulation with 8% trisodium citrate infusion and calcium substitution according to ionized calcium measurements
Drug: Regional citrate anticoagulation
Participants will undergo postdilution hemodiafiltration using standard unfractionated heparin anticoagulation according to routine clinical protocol.
Drug: Unfractionated heparin
Regional citrate anticoagulation using 8% trisodium citrate infusion during postdilution hemodiafiltration with calcium substitution adjusted according to ionized calcium levels.
Standard unfractionated heparin anticoagulation administered according to routine clinical protocol during postdilution hemodiafiltration.
Biocompatibility markers (C3a, PF4, TAT)
Comparison of complement activation marker C3a, platelet factor 4 (PF4), and thrombin-antithrombin complex (TAT) concentrations between citrate and heparin anticoagulation during postdilution hemodiafiltration.
Time frame: Before hemodiafiltration, after 15 minutes of treatment, and immediately before the end of the procedure.
Beta-2 microglobulin removal
Reduction ratio and total removal of beta-2 microglobulin during hemodiafiltration.
Time frame: Before, after 30 minutes and at the end of the procedure hemodiafiltration procedure.
instantaneous urea clearance after 30 minutes
instantaneous urea clearance after 30 minutes
Time frame: after 30 minutes of dialysis
p-cresyl sulfat removal
P-cresyl sulfat removal before, after 30 minutes and at the end of the procedure
Time frame: P-cresyl sulfat removal before, during and to the end of procedure
Ionized calcium kinetics
During citrate anticoagulation procedure
Time frame: During the 4-hour hemodiafiltration procedure
Extracorporeal circuit clotting score
Time frame: At the end of hemodiafiltration procedure.
Plan to share: No — Individual participant data will not be publicly available due to privacy and institutional data protection regulations.
No publications or documents are linked to this record.
Start is estimated for Jun 2026; primary completion for Dec 2026, 6 months later.
Of 349 non-industry interventional studies with no phase under Kidney Failure, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 47. This study's planned 6 months is below that.
Counting every sponsor, half of 427 studies reached it within 22 months; a quarter within 8 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Medical Centre Ljubljana →